Chemistry

吉非替尼基1,2,3-三唑杂化物

Gefitinib-based 1,2,3-triazole hybrids

Molecular hybrids combining the EGFR inhibitor gefitinib with 1,2,3-triazole moieties designed to enhance binding affinity and efficacy against non-small cell lung cancer / 结合了EGFR抑制剂吉非替尼与1,2,3-三唑基团的分子杂化物，旨在增强对非小细胞肺癌的结合亲和力和疗效。

Knowledge type: 实际应用
First proposed or discovered
Proposer: Turkey Farm member
Creator: 农场主
Last updated: 2026-11-09 18:06:40

Sub-knowledge points

Molecular docking / 工艺技术3D-QSAR modelingBinding energy calculations

Higher-order knowledge points

EGFR inhibitorsTriazole-based drugsNon-small cell lung cancer therapeutics

Main parameters and performance indicators

Gefitinib: Core EGFR tyrosine kinase inhibitor1,2,3-Triazole: Heterocyclic pharmacophoreEGFR: Epidermal Growth Factor Receptor targetNSCLC: Non-small cell lung cancer indication

Open problems

In vivo pharmacokinetic and toxicity profilesSelectivity over other kinasesResistance mechanisms

Related literature

ranked by community stars

Design and computational investigation of gefitinib-based 1,2,3-triazole hybrids as potential EGFR inhibitors for non-small cell lung cancer: 3D-QSAR and molecular modeling studyOpen source

吉非替尼基1,2,3-三唑杂化物

Sub-knowledge points

Higher-order knowledge points

Main parameters and performance indicators

Open problems

Related products and links